GlassScriptPhysician profile
Amy Dawn Anderson
NPI 1396362299
$4,943.44
in general payments reported to CMS, 2019-2025
19 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $559 · 2022: $746 · 2023: $693 · 2024: $1,175 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544 · Education: $93.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.31 |
| Education | $93.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,440.05 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $755.35 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $523.49 | 2021-2025 | Stelara, Tremfya, Remicade |
| E.R. Squibb & Sons, L.L.C. | $368.75 | 2021-2022 | |
| Pfizer INC. | $345.42 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $324.33 | 2025 | Zenpep, Vowst |
| Boston Scientific Corporation | $173.70 | 2024-2025 | Lumenis Pulse 120h |
| Regeneron Healthcare Solutions, INC. | $171.22 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $158.66 | 2021-2023 | Ocaliva |
| Celgene Corporation | $128.19 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $120.46 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $105.32 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $92.54 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.68 | 2025 | Xifaxan |
| Ardelyx, INC. | $49.56 | 2023-2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $34.85 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $32.67 | 2024 | Suflave |
| Ferring Pharmaceuticals INC. | $18.25 | 2023 | Rebyota |
| Tersera Therapeutics LLC | $14.95 | 2025 | Xermelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.